Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®Business Wire • 06/11/26
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/07/26
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026Business Wire • 04/23/26
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 03/02/26
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 03/02/26
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 GuidanceBusiness Wire • 03/02/26
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 02/26/26
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026Business Wire • 02/17/26
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total RevenueBusiness Wire • 01/08/26
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business Wire • 01/02/26
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent ApplicationBusiness Wire • 12/01/25
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/06/25